Innovative treatment for diabetes: a daily pill without the need for fasting

A Phase 3 study published in Nature Medicine tested an experimental pill called safiglipron in 810 patients with type 2 diabetes across 98 medical centers in China. The pill is taken once daily without fasting. At a dose of 90 mg, it showed an advantage in reducing glycated hemoglobin compared to an existing drug. Weight loss was modest and similar between treatments. The drug is still experimental and not approved for marketing.

A Phase 3 study published in the journal Nature Medicine examined an experimental pill called safiglipron for the treatment of type 2 diabetes. The study was conducted at 98 medical centers in China and involved 810 adults. Participants were divided into four groups: three received different doses of safiglipron, and the fourth received the existing drug dapagliflozin. All continued to receive metformin. After 32 weeks, all doses met the non-inferiority goal compared to dapagliflozin. At the 90 mg dose, superiority was found in reducing glycated hemoglobin. Weight loss was modest and similar between groups. The pill is taken once daily without the need for fasting or dietary restrictions. However, the drug is still experimental, and success in a trial does not equate to marketing approval. The study focused on blood sugar control, and no conclusions can be drawn about preventing heart attacks or long-term complications.